Journey Through Stage 1A Triple-Negative Breast Cancer and ECCT

She was 43 years old, and she had no idea that inside her right breast, something was quietly, methodically growing. It was a routine mammogram in late January 2025 that first raised the alarm. The radiologist's report noted what the films had caught: an extremely dense breast pattern, the kind that makes cancers harder to spot, and several small lesions that warranted a closer look. An ultrasound followed the same day. The images showed a hypoechoic lesion on her right breast, lobulated in shape, measuring less than a centimetre. In the left breast, a similar-looking lesion but slightly larger also spotted.

The pathology and PET scan results came back confirming the right breast lesion was cancer. Staged at T1bN0M0, officially, Stage 1A Triple-Negative Breast Cancer. Infiltrating ductal carcinoma. Grade 2 with Ki-67 index at 40 percent. Not the highest possible, but high enough to concern her because its small but aggressive not to be underestimated.

In March 2025, she underwent a wide local excision, a breast-conserving surgery in which the tumour and a margin of surrounding tissue are removed, leaving the breast largely intact. She woke from the anaesthetic with the tumour gone and the margins clean. But the oncologists were not yet satisfied. Even with clear margins and no nodal involvement, the aggressive nature of TNBC meant the risk of microscopic residual disease, cells too small to be seen on any scan, remained a concern. Chemotherapy was still recommended followed by radiotherapy. One of her physicians also raised the option of immunotherapy alongside chemotherapy, though she ultimately proceeded with a regimen of 4 cycles of Docetaxel and Cyclophosphamide.

She was not ready to say yes to all of it immediately. She sought other opinions. She read. She researched. She asked about ECCT, a complementary treatment she had heard about from a trusted contact. She wanted to know whether it could be used alongside chemotherapy. Whether it would interfere. Whether it might help protect her body through what was coming. She decided to start ECCT in March 2025. It was not a choice she made lightly but she understood the mathematics of TNBC recurrent rate: the statistics that said untreated residual disease in this subtype carried real high recurrent risk. She would do the chemotherapy. And she would keep doing ECCT alongside it.

Before

After

In early September 2025, approximately six months after ECCT began and roughly two months after the end of all conventional treatment, she returned for an ultrasound imaging review. The cancer site was clear. The benign nodules were stable. No new threats had emerged despite six months that included surgery, ECCT, four rounds of chemotherapy, and nine sessions of radiotherapy.

The blood test taken on September 2025 after her last chemotherapy dose told a story that surprised even those who had been monitoring her closely. Her haemoglobin, which had been down at 10.3 during peak chemotherapy, had risen to 13.7. Higher, in fact, than her pre-treatment baseline of 13.0.

Her creatinine, which had peaked at 85 µmol/L under chemotherapy stress, had fallen to just 46 µmol/L. Her eGFR, which had dipped to 75, was back above 90. Her kidneys had not merely recovered; they were performing better than they had at the start of the whole process.

Uric acid, which had reached 108 µmol/L during chemotherapy's cell-clearing phase, had normalised to 40 µmol/L.

Liver enzymes, ALT and AST were both in the low-normal range.

Her white cell counts and platelet count had returned to healthy baseline levels. The blood parameters stable and within good range, it was, by any clinical standard, a strong recovery.

April 2026, the final blood test in this account was taken. The results were, in a word, excellent.

Haemoglobin: 13.6 g/dL. White cell count: 5.1. Platelets: 309. All comfortably within the healthy reference range.

Her kidneys had continued their remarkable trajectory, creatinine at 48 µmol/L, eGFR now reaching 116 mL per minute, a figure that places her well above the threshold for excellent renal function.

Her liver enzymes sat at ALT 15, AST 19, entirely normal. Uric acid had settled at 32 µmol/L, within the lower end of the normal range.

There is no tidy ending to a cancer story. The scar on her right breast is her constant reminder of what was found, and what was done about it. But there are things she knows now that she did not know in January 2025, standing in the imaging suite with the radiologist's report in her hand.

She knows she completed four rounds of chemotherapy without a single dose reduction. She knows she received all nine planned sessions of radiotherapy. She knows her kidneys, which took the full weight of cytotoxic treatment, came through the other side performing better than they started. She knows her haemoglobin recovered fully, and quickly, to levels above her pre-treatment baseline. She knows that fourteen comprehensive scan and blood-test data points across more than a year show no evidence of disease recurrence.

She knows that she kept the vest on through all of it. Through the chemo days and the radiotherapy days and the hard nights and the mornings when she was too tired to want to bother. She kept it on.

Whether that is why her blood recovered the way it did, whether that is why her kidneys bounced back, why the imaging remained stable, why she tolerated the treatment better than she had feared, she cannot say with certainty. No one can. That is the nature of complementary medicine alongside conventional treatment: the variables are many, and the person is not a controlled experiment.

What she can say is this: she came to ECCT frightened, uncertain, and facing a diagnosis that demanded both courage and clear thinking. She left, or rather, she is still in the middle of a story that has, so far, gone better than she had any right to expect.

Names and identifying details have been covered to protect patient privacy. All medical data is drawn directly from verified clinical records and verifiable. This testimonial is for educational purposes only and does not constitute medical advice. Individual outcomes may vary.